Martine Piccart
A5087380706- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Gene expression and cancer classification
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- PI3K/AKT/mTOR signaling in cancer
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- Ovarian cancer diagnosis and treatment
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Bioinformatics and Genomic Networks
- Cancer Risks and Factors
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Breast Lesions and Carcinomas
- Radiomics and Machine Learning in Medical Imaging
Université Libre de Bruxelles
2016-2025
Institut Jules Bordet
2016-2025
Breast International Group
2014-2024
Fondazione IRCCS Istituto Nazionale dei Tumori
2013-2023
Althaia
2021-2023
Sonnenhalde (Switzerland)
2023
International Breast Cancer Study Group
2004-2021
Memorial Sloan Kettering Cancer Center
2013-2019
Peter MacCallum Cancer Centre
2007-2019
Chinese Academy of Medical Sciences & Peking Union Medical College
2012-2019
Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage completion chemotherapy.
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target rapamycin (mTOR) intracellular signaling pathway. In early studies, mTOR inhibitor everolimus added showed antitumor activity.In this phase 3, randomized trial, we compared and exemestane versus placebo (randomly assigned a 2:1 ratio) 724 patients hormone-receptor-positive advanced who had recurrence or progression while receiving previous nonsteroidal aromatase adjuvant setting treat...
Background: Histologic grade in breast cancer provides clinically important prognostic information. However, 30%–60% of tumors are classified as histologic 2. This is associated with an intermediate risk recurrence and thus not informative for clinical decision making. We examined whether was gene expression profiles cancers such could be used to improve grading. Methods: analyzed microarray data from 189 invasive carcinomas three published datasets carcinomas. identified differentially...
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought provide prospective evidence the utility addition standard clinical–pathological criteria selecting patients for adjuvant chemotherapy.
Purpose Previous preclinical and clinical data suggest that the immune system influences prognosis response to chemotherapy (CT); however, relevance has yet be established in breast cancer (BC). We hypothesized increased lymphocytic infiltration would associated with good benefit from immunogenic CT—in this case, anthracycline-only selected BC subtypes. Patients Methods investigated relationship between quantity location of infiltrate at diagnosis outcome 2009 node-positive samples BIG 02-98...
A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal validate the an independent group of patients.Patients (n = 307, 137 events after a median follow-up 13.6 years) from five European centers were divided into high- and low-risk groups based on gene classification clinical risk classifications. Patients assigned if their 5-year distant metastasis-free survival probability as estimated by greater than 90%. clinicopathologic...
Pertuzumab increases the rate of pathological complete response in preoperative context and overall survival among patients with metastatic disease when it is added to trastuzumab chemotherapy for treatment human epidermal growth factor receptor 2 (HER2)–positive breast cancer. In this trial, we investigated whether pertuzumab, adjuvant chemotherapy, improves outcomes HER2-positive early
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.
Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after years. The MA.17 trial, which was designed to determine whether extended therapy the aromatase inhibitor letrozole reduces risk such late recurrences, stopped early an interim analysis showed that improved disease-free survival. This report presents updated findings from trial.Postmenopausal completing treatment were randomly assigned a planned (n = 2593) or placebo 2594). primary endpoint...
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which expressed in majority cancers, coupled to SN-38 (topoisomerase I inhibitor) through proprietary hydrolyzable linker.
Abstract Purpose: Recently, a 76-gene prognostic signature able to predict distant metastases in lymph node–negative (N−) breast cancer patients was reported. The aims of this study conducted by TRANSBIG were independently validate these results and compare the outcome with clinical risk assessment. Experimental Design: Gene expression profiling frozen samples from 198 N− systemically untreated done at Bordet Institute, blinded data independent Veridex. Genomic defined Veridex, data....
CD4⁺ T cells are critical regulators of immune responses, but their functional role in human breast cancer is relatively unknown. The goal this study was to produce an image infiltrating tumors using limited ex vivo manipulation better understand the differences associated with patient prognosis. We performed comprehensive molecular profiling isolated from untreated invasive primary and found that cell subpopulations included follicular helper (Tfh) cells, which have not previously been...
A number of microarray studies have reported distinct molecular profiles breast cancers (BC), such as basal-like, ErbB2-like, and two to three luminal-like subtypes. These were associated with different clinical outcomes. However, although the basal ErbB2 subtypes are repeatedly recognized, identification estrogen receptor (ER) -positive has been inconsistent. Therefore, refinement their definition is needed.We previously a gene expression grade index (GGI), which defines histologic based on...